Apr 11, 2024 8:00am EDT Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial
Mar 28, 2024 8:15am EDT Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
Mar 25, 2024 8:15am EDT Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
Feb 21, 2024 8:15am EST Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
Feb 14, 2024 1:00pm EST Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
Feb 06, 2024 8:30am EST Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
Jan 25, 2024 8:30am EST Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
Jan 19, 2024 7:45am EST Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
